Transcatheter aortic valve replacement (TAVR) patients who undergo an additional transcatheter edge-to-edge repair (TEER) or valve replacement to treat concomitant severe valvular heart disease (VHD) show lower 1-year and 5-year mortality rates than patients whose other valvular diseases remain untreated, a new study shows.